HMGB1 and cancer: In patients with various types of cancer, HMGB1 overexpression is correlated with poorer prognosis; HMGB1 overexpression is implicated in poorer overall survival (OS) (HR: 1.99; 95% CI, 1.71–2.31) and progression-free survival (PFS) (HR: 2.26; 95% CI, 1.65–3.10) in a variety of different cancer types.